NL7906542A - 1-methyl-4-piperidinolesters, werkwijze voor de berei- ding van dergelijke esters en geneesmiddelen met als werkzaam bestanddeel een dergelijke ester. - Google Patents
1-methyl-4-piperidinolesters, werkwijze voor de berei- ding van dergelijke esters en geneesmiddelen met als werkzaam bestanddeel een dergelijke ester. Download PDFInfo
- Publication number
- NL7906542A NL7906542A NL7906542A NL7906542A NL7906542A NL 7906542 A NL7906542 A NL 7906542A NL 7906542 A NL7906542 A NL 7906542A NL 7906542 A NL7906542 A NL 7906542A NL 7906542 A NL7906542 A NL 7906542A
- Authority
- NL
- Netherlands
- Prior art keywords
- methyl
- formula
- esters
- piperidyl
- quinolyl
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 17
- 238000002360 preparation method Methods 0.000 title claims description 6
- 230000008569 process Effects 0.000 title claims description 5
- BAUWRHPMUVYFOD-UHFFFAOYSA-N 1-methylpiperidin-4-ol Chemical class CN1CCC(O)CC1 BAUWRHPMUVYFOD-UHFFFAOYSA-N 0.000 title description 5
- 150000002148 esters Chemical class 0.000 title description 5
- 229940126601 medicinal product Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 22
- -1 (8-trifluoromethyl-4-quinolyl) -amino Chemical group 0.000 claims description 17
- 150000003839 salts Chemical class 0.000 claims description 9
- 239000002253 acid Substances 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 6
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 5
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 3
- 150000007513 acids Chemical class 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 125000001309 chloro group Chemical class Cl* 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 241000700159 Rattus Species 0.000 description 6
- GWOFUCIGLDBNKM-UHFFFAOYSA-N glafenine Chemical compound OCC(O)COC(=O)C1=CC=CC=C1NC1=CC=NC2=CC(Cl)=CC=C12 GWOFUCIGLDBNKM-UHFFFAOYSA-N 0.000 description 6
- 229960001650 glafenine Drugs 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 229960002895 phenylbutazone Drugs 0.000 description 3
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- HXEWMTXDBOQQKO-UHFFFAOYSA-N 4,7-dichloroquinoline Chemical compound ClC1=CC=NC2=CC(Cl)=CC=C21 HXEWMTXDBOQQKO-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000001354 painful effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- SLAMLWHELXOEJZ-UHFFFAOYSA-M 2-nitrobenzoate Chemical compound [O-]C(=O)C1=CC=CC=C1[N+]([O-])=O SLAMLWHELXOEJZ-UHFFFAOYSA-M 0.000 description 1
- BWWHTIHDQBHTHP-UHFFFAOYSA-N 2-nitrobenzoyl chloride Chemical compound [O-][N+](=O)C1=CC=CC=C1C(Cl)=O BWWHTIHDQBHTHP-UHFFFAOYSA-N 0.000 description 1
- RLQZIECDMISZHS-UHFFFAOYSA-N 2-phenylcyclohexa-2,5-diene-1,4-dione Chemical compound O=C1C=CC(=O)C(C=2C=CC=CC=2)=C1 RLQZIECDMISZHS-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- LLRQVSZVVAKRJA-UHFFFAOYSA-N 4-chloro-7-(trifluoromethyl)quinoline Chemical compound ClC1=CC=NC2=CC(C(F)(F)F)=CC=C21 LLRQVSZVVAKRJA-UHFFFAOYSA-N 0.000 description 1
- LINGICLAECZKAW-UHFFFAOYSA-N 4-chloro-8-(trifluoromethyl)quinoline Chemical compound C1=CN=C2C(C(F)(F)F)=CC=CC2=C1Cl LINGICLAECZKAW-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 206010036030 Polyarthritis Diseases 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 201000002661 Spondylitis Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000010531 catalytic reduction reaction Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 210000000885 nephron Anatomy 0.000 description 1
- 150000002828 nitro derivatives Chemical class 0.000 description 1
- 229910017464 nitrogen compound Inorganic materials 0.000 description 1
- 150000002830 nitrogen compounds Chemical class 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 208000030428 polyarticular arthritis Diseases 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000006384 traumatic process Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH922978 | 1978-09-01 | ||
CH922978 | 1978-09-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
NL7906542A true NL7906542A (nl) | 1980-03-04 |
Family
ID=4349742
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NL7906542A NL7906542A (nl) | 1978-09-01 | 1979-08-31 | 1-methyl-4-piperidinolesters, werkwijze voor de berei- ding van dergelijke esters en geneesmiddelen met als werkzaam bestanddeel een dergelijke ester. |
Country Status (18)
Country | Link |
---|---|
US (1) | US4259335A (ja) |
JP (1) | JPS5535087A (ja) |
AR (1) | AR219814A1 (ja) |
AU (1) | AU5048479A (ja) |
BE (1) | BE878557A (ja) |
CA (1) | CA1123830A (ja) |
DD (1) | DD145754A5 (ja) |
DE (1) | DE2935329A1 (ja) |
ES (1) | ES483463A1 (ja) |
FR (1) | FR2434808A1 (ja) |
GB (1) | GB2031412B (ja) |
IL (1) | IL58154A0 (ja) |
IT (1) | IT7950135A0 (ja) |
NL (1) | NL7906542A (ja) |
OA (1) | OA06331A (ja) |
PT (1) | PT70138A (ja) |
SE (1) | SE7907251L (ja) |
ZA (1) | ZA794631B (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS57155953A (en) * | 1981-03-19 | 1982-09-27 | Snow Brand Milk Prod Co Ltd | Preparation of frozen food having transparent ice shell |
FR2503163A1 (fr) * | 1981-04-03 | 1982-10-08 | Roussel Uclaf | Nouveaux derives de l'acide 3-/4-quinoleinyl-amino/2-thiophene carboxylique, leur procede de preparation et leur application comme medicament |
NZ202320A (en) * | 1981-11-14 | 1985-05-31 | Recordati Chem Pharm | Anthraniloyloxyalkanoates and pharmaceutical compositions containing such |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL131732C (ja) * | 1966-03-31 | |||
FR6493M (ja) * | 1967-06-29 | 1968-11-25 | ||
FR7870M (ja) * | 1968-11-08 | 1970-04-27 | ||
US3579520A (en) * | 1969-08-21 | 1971-05-18 | Sterling Drug Inc | 4-(4-piperidinyl-methyl or -1-ethyl) amino-7-chloroquinolines |
US3971789A (en) * | 1972-10-21 | 1976-07-27 | John Wyeth & Brother Limited | O-(4-Quinolylamino)benzamides |
FR2233059B1 (ja) * | 1973-06-13 | 1976-09-03 | Roussel Uclaf |
-
1979
- 1979-08-01 FR FR7919760A patent/FR2434808A1/fr active Granted
- 1979-08-03 CA CA333,161A patent/CA1123830A/fr not_active Expired
- 1979-08-06 US US06/064,091 patent/US4259335A/en not_active Expired - Lifetime
- 1979-08-17 ES ES483463A patent/ES483463A1/es not_active Expired
- 1979-08-31 GB GB7930274A patent/GB2031412B/en not_active Expired
- 1979-08-31 AU AU50484/79A patent/AU5048479A/en not_active Abandoned
- 1979-08-31 DD DD79215307A patent/DD145754A5/de unknown
- 1979-08-31 NL NL7906542A patent/NL7906542A/nl not_active Application Discontinuation
- 1979-08-31 DE DE19792935329 patent/DE2935329A1/de not_active Withdrawn
- 1979-08-31 SE SE7907251A patent/SE7907251L/ not_active Application Discontinuation
- 1979-08-31 OA OA56890A patent/OA06331A/xx unknown
- 1979-08-31 BE BE0/196985A patent/BE878557A/fr unknown
- 1979-08-31 PT PT70138A patent/PT70138A/pt unknown
- 1979-08-31 JP JP11053179A patent/JPS5535087A/ja active Pending
- 1979-08-31 IT IT7950135A patent/IT7950135A0/it unknown
- 1979-08-31 ZA ZA00794631A patent/ZA794631B/xx unknown
- 1979-08-31 AR AR277918A patent/AR219814A1/es active
- 1979-08-31 IL IL58154A patent/IL58154A0/xx unknown
Also Published As
Publication number | Publication date |
---|---|
JPS5535087A (en) | 1980-03-11 |
DE2935329A1 (de) | 1980-03-20 |
PT70138A (fr) | 1979-09-01 |
FR2434808A1 (fr) | 1980-03-28 |
AU5048479A (en) | 1980-03-06 |
FR2434808B1 (ja) | 1983-12-23 |
SE7907251L (sv) | 1980-03-02 |
US4259335A (en) | 1981-03-31 |
AR219814A1 (es) | 1980-09-15 |
GB2031412A (en) | 1980-04-23 |
GB2031412B (en) | 1982-09-15 |
IL58154A0 (en) | 1979-12-30 |
OA06331A (fr) | 1981-06-30 |
ES483463A1 (es) | 1980-04-16 |
CA1123830A (fr) | 1982-05-18 |
DD145754A5 (de) | 1981-01-07 |
ZA794631B (en) | 1980-08-27 |
IT7950135A0 (it) | 1979-08-31 |
BE878557A (fr) | 1980-02-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE2513157C2 (ja) | ||
JPH0641475B2 (ja) | 置換アルファアミノ酸、その製法および医薬 | |
US20070060544A1 (en) | 4-Nitro-2-[(4'-methoxy)-phenoxy]-methanesulfonanilide derivatives and their pharmaceutical use | |
JPH01190688A (ja) | ピロリチジン化合物およびその用途 | |
JPS5921850B2 (ja) | 新ナフタレン誘導体の製法 | |
US2835702A (en) | Benzene 1, 3 disulfonamides possessing diuretic properties | |
HU181147B (en) | Process for preparing substituted heterocyclin phenoxamines | |
NZ203317A (en) | 2,3-diaryl-5-halo-thiophene derivatives;pharmaceutical compositions | |
NL7906542A (nl) | 1-methyl-4-piperidinolesters, werkwijze voor de berei- ding van dergelijke esters en geneesmiddelen met als werkzaam bestanddeel een dergelijke ester. | |
DE68912263T2 (de) | 4-Methyl-5[2-(4-phenyl-1-piperazinyl)-ethyl]-Thiazolderivate, ihre Herstellung und Zusammenstellungen, die sie enthalten. | |
WO2015055114A1 (zh) | 二苯乙烷衍生物及其应用 | |
JPH01228975A (ja) | ベンゾチアジン―1,1―ジオキシド誘導体及びそれを含有する医薬組成物 | |
US3127401A (en) | Z-benzyl-j | |
JPS6310720A (ja) | 5−リポキシゲナ−ゼ阻害剤および抗アレルギ−剤 | |
TW445261B (en) | A substituted thiophenylalkenylcarboxylic acid guanidide compound having the cellular Na<SP>+</SP>/H<SP>+</SP> exchanger inhibitory activity, the preparation processes and the pharmaceutical compositions thereof | |
US4272529A (en) | O-Alcoxycarbonylphenyl esters of anthranilic acid with therapeutical activity, method for their preparation and related pharmaceutical composition | |
JPS6056142B2 (ja) | チアゾリンの新規誘導体およびその医薬としての適用 | |
JPH02502534A (ja) | 1‐メチル‐β‐オキソ‐α‐(フェニルカルバモイル)‐2‐ピロールプロピオニトリルのトロメタミン塩 | |
WO1994006762A1 (en) | Non-metabolizable clomiphene analogs for treatment of tamoxifen-resistant tumors | |
US3466373A (en) | Analgesic and anti-inflammatory composition consisting essentially of 2-(2,3-xylylamino)-nicotinic acid | |
JPH0196158A (ja) | 抗炎症剤 | |
US3857880A (en) | Cyclopropane carboxylic acid derivatives | |
US4038278A (en) | 4-aminopyrimidium derivatives and preparation thereof | |
Genzer et al. | The Resolution of Parsidol | |
DE68921746T2 (de) | Benzothiazin-1,1-dioxid-Derivate. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
BV | The patent application has lapsed |